“Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn ...

Adverse drug events (ADEs)--injuries caused by medications-- are estimated to rank among the leading causes of death in the United States and represent a major, often preventable threat to patient ...

Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

Add Yahoo as a preferred source to see more of our stories on Google. FDA Commissioner Martin Makary on Thursday announced a move away from animal-based drug testing in favor of human-based methods ...

The FDAAA did not significantly alter the overall time to first postmarket safety action for novel therapeutics. Earlier safety actions were observed within the first five years post-approval, ...

India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.

Most of the oncology drugs that received the FDA’s accelerated approval from 2011 to 2020 had some kind of FDA postmarketing safety action, according to a research letter. Safety actions included ...

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug ...

Generic drugs account for more than 90 percent of prescriptions filled in the United States. Recent studies have found concering variability in quality and safety America’s generic drug supply, most ...

US Food and Drug Administration layoffs appear to be affecting programs that track drug safety. Fired workers from the Division of Drug Information, which conducts safety monitoring, say the DDI team ...

The evaluation of drug safety in clinical trials is a critical element of the drug development process, ensuring that therapeutic benefits outweigh potential harms. Clinical trials, particularly in ...